WO2016110167A1 - Applications of 20(r)-ginsenosides rg3 in preparing medicament or healthcare product for use in treatment of osteoporosis and medicament - Google Patents

Abstract

Applications of 20(R)-ginsenosides Rg3 in preparing a medicament for use in treatment of osteoporosis and the medicament or a healthcare product comprising 20(R)-ginsenosides Rg3, where the content of 20(R)-ginsenosides Rg3 is ≥ 1%.

Description

Application of 20(R)-ginsenoside Rg3 in preparing medicines or health care products for treating osteoporosis Technical field

The invention belongs to the field of medicine, and relates to a medicine or health food for treating osteoporosis, in particular to an application of a traditional Chinese medicine ginseng extract component in treating osteoporosis medicine or health food.

Background technique

Osteoporosis is mainly divided into primary and secondary, primary except for idiopathic, divided into type I and type II, type I, also known as postmenopausal osteoporosis, is a high conversion type, the main reason It is a deficiency of estrogen; type II, also known as senile osteoporosis, is a low-transformation type due to ageing. Osteoporosis is caused by many factors. Its basic pathological mechanism is the defect of coupling of bone resorption and bone formation during bone metabolism, resulting in imbalance of calcium and phosphorus metabolism in the human body and causing a decrease in bone density. Clinical symptoms.

The most common symptom of primary osteoporosis is more common in low back pain, accounting for 70% to 80% of patients with pain. The pain spreads along the spine to the sides, and the pain is relieved when lying on the back or sitting. When standing up or standing upright, the pain is exacerbated during sedentary, the pain during the day is light, and the night and morning wake up, the waist bends, the muscles move, the cough, The stool is aggravated when it is hard. Bone pain can occur when the bone mass is lost by more than 12%. In elderly osteoporosis, the vertebral trabecular bone atrophy, the number is reduced, the vertebral body is compressed and deformed, the spine is flexed, and the back rash muscle is used to correct the flexion of the spine, double the contraction, muscle fatigue and even paralysis. New thoracolumbar vertebral compression fractures can also produce acute pain. Spinal spinous processes in the corresponding sites can have strong tenderness and snoring pain. Generally, they can be gradually relieved after 2 to 3 weeks, and some patients may have chronic low back pain. If the corresponding spinal nerves are compressed, it can cause radiation pain in the extremities, sensory dyskinesia in both lower extremities, intercostal neuralgia, post-sternal pain similar to angina pectoris, and upper abdominal pain similar to acute abdomen. If the spinal cord and the horsetail are pressed, the bladder and rectum function will be affected. More often after the pain. The front part of the vertebral body is composed of cancellous bone, and this part is the pillar of the body. It has a large weight, especially the 11th and 12th thoracic vertebrae and the 3rd lumbar vertebrae. The load is larger, it is easy to compress and deform, and the spine is tilted forward. The back curvature is intensified, forming a hunchback. As the age increases, the osteoporosis increases, and the kyphosis curvature increases, causing the knee joint to be significantly restrained. Each person has 24 vertebral bodies. The height of each vertebral body is about 2cm. The vertebral body is compressed when the elderly are osteoporosis. Each vertebral body is shortened by about 2mm, and the body length is shortened by an average of 3~6cm. Chest and lumbar compression fractures, posterior curvature of the spine, and thoracic deformity can significantly reduce lung capacity and maximum ventilation. Patients often have symptoms such as chest tightness, shortness of breath, and difficulty breathing.

The diagnosis of postmenopausal and senile osteoporosis, first need to rule out secondary osteoporosis caused by various other reasons, such as hyperparathyroidism and multiple myeloma, osteomalacia, renal bone Malnutrition, osteogenesis in children, metastases, leukemia, and lymphoma.

Graded diagnosis of osteoporosis: normal BMD or BMC within 1 standard deviation (SD) of normal adult bone mineral density; osteopenia for BMD or BMC is 1 to 2.5 lower than normal adult bone mineral density Standard deviation; osteoporosis is more than 2.5 standard deviations of BMD or BMC than normal adult bone mineral density; severe osteoporosis is more than 2.5 standard deviations lower than BMD or BMC than normal adult bone mineral density with One or more fragility fractures. BMD or BMC can be measured in the central axis or peripheral bone in this diagnostic criteria.

Clinically used drugs for the prevention and treatment of osteoporosis include: calcium preparations, including Yidile, Kaisili, Calcium D, Leli, calcium gluconate oral solution, Longchang calcium + D oral solution, Jinde calcium , giant energy calcium and ultra-micro calcium; inhibit bone resorption drugs, such as dehydrogenation, Premarin tablets and Li Weiai; bisphosphonates, such as Fushanmei, Linlin, Bondlin and Gili Shuning; Osteogenic drugs, such as levidine; vitamins that promote mineralization, such as Fa-en (lα-hydroxyvitamin D3), Luo calcium (calcium triol), Menggewang (alfacalcitol), Qing (Alpha Calcium Tablets).

Surgical treatment is required only after fractures due to osteoporosis. The purpose is to treat the fracture and restore normal function as soon as possible.

The famous medicinal materials of ginseng Chinese medicine, modern medical research shows that the main functions and effects of ginseng are: the role of the central nervous system, anti-cancer anti-tumor effect, immune function regulation, anti-diabetes effect, enhance liver function, cardiovascular and cerebrovascular disorders Improvement, anti-arteriosclerosis, blood pressure regulation, and menopausal disorders and anti-osteoporosis, anti-fatigue, anti-oxidation, anti-aging and so on. As the main active ingredient of ginseng, ginsenoside is widely studied and used. Among them, 20(R)-ginsenoside Rg3 is the most attractive. It is the main active ingredient of ginseng and has good safety. It has been made into anti-tumor oral preparation. It has been used clinically and has been intensively studied as an injection.

The inventors have extracted the active ingredient 20(R)-ginsenoside Rg3, and 20(R)-ginsenoside Rg3, from the ginseng medicinal materials by a large number of modern scientific researches using advanced separation and purification techniques. The corresponding pharmaceutical preparations have been studied for pharmacodynamics and pharmacology of osteoporosis. The results show that 20(R)-ginsenoside Rg3 monomer has clear pharmacological effects, strong efficacy in treating osteoporosis, low toxicity and safety. High in sex, it can provide a highly effective and low-toxic drug for the treatment of osteoporosis.

Summary of the invention

The primary object of the present invention is to provide the performance and efficacy of 20(R)-ginsenoside Rg3 in the treatment of osteoporosis in view of the technical problems existing in the above-mentioned drugs or health care products for treating osteoporosis, and to address the above-mentioned existing A problem with the technology provides a new medicinal use of 20(R)-ginsenoside Rg3, a new application in the treatment of osteoporosis drugs or health foods.

In order to achieve the object of the present invention, an aspect of the present invention provides a use of 20(R)-ginsenoside Rg3 for the preparation of a medicament or a health care product for treating osteoporosis.

In the process of screening natural active ingredients having an effect of treating osteoporosis, the inventors found that 20(R)-ginsenoside Rg3 in the chemical composition of ginseng has a strong therapeutic effect on osteoporosis.

Wherein the medicament or health care product consists of 20(R)-ginsenoside Rg3 and a pharmaceutically acceptable carrier.

Wherein the 20(R)-ginsenoside Rg3 content is ≥1%, preferably ≥30%, further preferably ≥60%, still more preferably ≥80%, still more preferably ≥98%.

In particular, the 20(R)-ginsenoside Rg3 content is from 1% to 98%; preferably from 30% to 80%, more preferably 60%.

In particular, pharmaceutically acceptable carriers are generally approved by health care professionals for this purpose and as inactive ingredients of the agent. A compilation of pharmaceutically acceptable carriers can be found in the Handbook of Pharmaceutical excipients, 2nd edition, edited by A. Wade and PJ Weller; published by the American Pharmaceutical Association, Washington and The Pharmaceutical Press, London, 1994) found in the reference book.

In particular, the carrier comprises an excipient such as starch, water or the like; a lubricant such as magnesium stearate or the like; a disintegrating agent such as microcrystalline cellulose; a filler such as lactose; and a binder, Such as pregelatinized starch, dextrin, etc.; sweeteners; antioxidants; preservatives, flavors, spices, etc.

Wherein the medicament is in the form of a tablet, a capsule, a pill, a powder, a granule, a syrup, a solution, an emulsion, an injection, a spray, an aerosol, a gel, a cream, a tincture, a cataplasm, a rubber. It is in the form of a plaster or a plaster.

In particular, the 20(R)-ginsenoside Rg3 content is ≥1%, preferably ≥30%, further preferably ≥60%, still more preferably ≥80%, still more preferably ≥98%.

Another aspect of the present invention provides a medicament or a health care product for treating osteoporosis containing 20(R)-ginsenoside Rg3.

Wherein the 20(R)-ginsenoside Rg3 content is ≥1%, preferably ≥30%, further preferably ≥60%, still more preferably ≥80%, still more preferably ≥98%.

In particular, the 20(R)-ginsenoside Rg3 content is preferably from 1% to 98%, more preferably from 30% to 80%, still more preferably from 60%.

In particular, the ratio of the weight of the 20(R)-ginsenoside Rg3 to the total weight of the pharmaceutical or nutraceutical product is from 0.01 to 10:100, preferably from 0.1 to 10:100, further preferably from 1 to 10:100. .

In particular, the medicine or health care product is also extracted from Astragalus membranaceus, Salvia miltiorrhiza extract, Epimedium extract, Hawthorn extract, licorice extract, black sesame extract, ginger extract, grape seed extract, and pomegranate extract. One or more of a plant, a plant essential oil, arbutin, vitamin C and its derivatives, or vitamin E and its derivatives.

The medicament can be prepared into various dosage forms by methods well known in the art, such as tablets, capsules, pills, powders, granules, syrups, solutions, injections, sprays, aerosols, gels, creams. Agent, expectorant, cataplasm, rubber plaster or plaster.

The present invention also provides a method of treating osteoporosis comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition of 20(R)-ginsenoside Rg3, wherein the therapeutically effective amount is 0.6 to 12 mg/kg·d. It is preferably 1 to 6 mg/kg·d, and more preferably 1.5 to 3 mg/kg·d.

The term "therapeutically effective amount" as used herein, unless otherwise indicated, is the amount of the agent in need of an effective effect; the "therapeutically effective amount" is adjustable and variable, and is ultimately determined by the medical personnel, the factors considered including the route of administration. And the general nature of the formulation, the recipient's weight, age, etc., and the nature and severity of the condition being treated.

Compared with the prior art, the present invention has the following distinct advantages:

1. The present invention excavates a new medicinal value for the known compound 20(R)-ginsenoside Rg3, which is used for preventing and treating osteoporosis, and can be prepared into a medicament for treating osteoporosis or a health food. , thus opening up a new field for the application of ginseng herbs.

2. A series of experimental studies of the present invention demonstrate that 20(R)-ginsenoside Rg3 has significant efficacy in the treatment of osteoporosis.

3. The 20(R)-ginsenoside Rg3 of the invention has strong pharmacological action, has remarkable efficacy in treating osteoporosis, has quick effect, small toxic and side effects, good safety, and can be taken for a long time, and has good medicinal prospects.

4. The raw materials of the invention have rich sources, low cost, safe clinical use, simple preparation process, can be made into various dosage forms, and have small dosage and convenient use, so it is easy to promote.

5. The invention can prepare a medicament for treating osteoporosis by using a single component of 20(R)-ginsenoside Rg3 active ingredient, and can also use 20(R)-ginsenoside Rg3 and other active ingredients (for example, with astragalus and salvia miltiorrhiza) , Epimedium, hawthorn, licorice, black sesame extract, ginger extract, grape seed extract, garnet extract, plant essential oil, arbutin, vitamin C and its derivatives or vitamin E and its derivatives) Recipe to prepare a compound drug for the treatment of osteoporosis.

Specific embodiment

The beneficial effects of the formulations of the present invention are further described below by way of specific embodiments. These examples are merely illustrative and are not intended to limit the scope of the invention in any way. It should be understood by those skilled in the art that the details and forms of the technical solutions of the present invention may be modified or replaced without departing from the spirit and scope of the invention, but such modifications and substitutions fall within the scope of the present invention.

The experimental methods in the following examples which do not specify the specific experimental conditions are usually in accordance with conventional conditions or according to the conditions recommended by the manufacturer. The beneficial effects of the medicament of the present invention are further illustrated by the following test examples, which include the pharmacodynamic test of the medicament of the present invention.

Example 1 Rg3 tablet

1. Prepare raw materials according to the following ratio

After ginsenoside Rg3 and starch were uniformly mixed, granules were prepared, and talc powder and magnesium stearate were added and uniformly mixed, and then pressed into 10,000 tablets.

Example 2 Rg3 capsule

1. Prepare raw materials according to the following ratio

Ginsenoside Rg3 (content 63%) 200g

Starch 1000g

The ginsenoside Rg3 and the starch were uniformly mixed, and then filled into capsules to prepare 10,000 tablets.

Example 3 Rg3 granules

1. Prepare raw materials according to the following ratio

Ginsenoside Rg3 (content 98%) 10g

Microcrystalline cellulose 1000g

The ginsenoside Rg3 and the microcrystalline cellulose were uniformly mixed to form granules, which were bagged and made into 10,000 bags.

Example 4 Rg3 tablet

1. Prepare raw materials according to the following ratio

After ginsenoside rg3, licorice extract, vitamin C and starch were uniformly mixed, granulation was carried out, and talc powder and magnesium stearate were added and mixed, and then pressed into 10,000 tablets.

Example 5 Rg3 capsule

Ginsenoside Rg3, Astragalus membranaceus extract, vitamin C and starch were uniformly mixed and filled into capsules to prepare 10,000 tablets.

Example 6 Rg3 granules

Ginsenoside Rg3, hawthorn extract, vitamin C and sucrose powder were mixed and granulated, and then bagged to prepare 10,000 bags.

Example 7 Rg3 oral solution

1. Prepare raw materials according to the following ratio

The whole party will eventually add deionized water to 1000ml.

After ginsenoside Rg3 is dissolved in a small amount of ethanol, Danshen extract, black sesame extract and glucose syrup are added, and finally deionized water is added to 100 ml to obtain.

Test Example 1 20(R)-ginsenoside Rg3 anti-osteoporosis pharmacodynamic experiment

1 experimental material

1.1 drugs and reagents

20(R)-ginsenoside Rg3, provided by Dalian Fusheng Natural Medicine Development Co., Ltd., Pharmaceutical Preparation Laboratory, batch number: 2012303; ginsenoside Rg3 standard provided by China National Institute for the Control of Pharmaceutical and Biological Products, and HPLC calibration, 98.2% ;

Positive control drug: Nilestriol tablets were produced by Beijing Sihuan Pharmaceutical Co., Ltd., National Pharmaceutical Standard Hl1020123, lmg/tablet, 10 tablets/box. The mixture was ground in a mortar before use and suspended in a suspension of 0.5% CMC-Na to form a 0.05 mg/ml suspension;

Negative control drug: normal saline, provided by Ningxia Qiyuan National Medicine Co., Ltd., batch number 100221-1;

Anesthetic: 10% chloral hydrate;

The remaining reagents were of analytical grade.

1.2 experimental animals

Eight-month-old Wistar female rats weighing 220-310 g were purchased from Experimental Animal Center of Dalian Medical University, and the quality certificate number was SCXK (13) 2012-0003.

1.3 experimental instruments

BIO-RAD type washing machine, Model-680 type microplate reader, DHP-9082 type electrothermal constant temperature incubator, Olympus AU2700 automatic biochemical analyzer, TD5A-WS desktop low speed centrifuge, etc. are provided by Ningxia Medical University.

2 experimental methods

2.1 modeling method

Ovariectomized model rats: 10% chloral hydrate 30mg/kg intraperitoneal injection anesthesia, strict aseptic operation, take the midline incision into the abdominal cavity, completely remove the bilateral ovaries, completely stop bleeding, suture the muscles and skin in two layers, remove The ovary was confirmed by pathology: the sham operation group had the same incision as before, and the left and right mesenteric segments were removed after entering the abdominal cavity. The bilateral ovaries were removed and placed in vitro for 1 min. The weight was basically the same as that of the bilateral ovaries. , hemostasis suture. The wound was sprinkled with penicillin powder, and the wound was not infected after the operation, and healed on schedule. There was no periodic change in the continuous vaginal smear 5 days after oophorectomy, and the uterus was atrophied at autopsy.

2.2 Animal grouping and administration methods

After modeling, 48 Wistar rats were randomly divided into RG3 high-dose group (high-dose group), RG3 middle-dose group (middle-dose group), RG3 low-dose group (low-dose group), and positive. There were 6 groups in the control group, model blank group and sham operation group, and 8 rats in each group were administered half a month after operation. The model group was given normal saline, 2 ml/kg body weight, once daily for 12 weeks, and the sham operation group was treated with the same model group. The high, medium and low dose groups of RG3 were given 6 mg/kg, 3 mg/kg and 1.5 mg/kg, respectively. Once a day for 12 consecutive weeks. The positive control group was intragastrically administered with nylestriol 0.15 mg/kg once a week, and distilled water 6 times per week, 2 ml/kg for 12 weeks. Freely drink water and eat for 12 weeks in the same environment to control the amount of food.

After 12 weeks of drug intervention, each group of animals was anesthetized by intraperitoneal injection of 10% chloral hydrate (30 ml/kg) after the last administration. The prone position was placed on the dual-energy X-ray bone density diagnostic apparatus, and the small animal measurement software was used. The 1-5 lumbar vertebrae and femur were scanned in the resolution mode. The scanning parameters were: l.0xl.0mm, 60mm/s, 12.00cm REV3.9.3/2.1.0, precision 1.5%, accuracy 90%. .

3 experimental results

With SPSS11.0 processing, all data were tested for normality and homogeneity of variance. The results of bone mineral density measurement in each group were compared by one-way analysis of variance. The SNK-q test was used to compare the two groups. The test level was α=0.05. The results are shown in Table 1.

Table 1 Effect of RG3 on bone mineral density in ovariectomized female rats (x±s n=8)

Note: Compared with the model group *: P < 0.01, **: P < 0.001.

From the experimental results in Table 1, it can be seen that the bone density of femur, lumbar vertebrae and whole body decreased significantly in the model group compared with the sham operation group (p<0.01), indicating that the bone mineral content of the ovariectomized female rats decreased significantly; the high and medium doses of RG3 Compared with the model group, the bone density of the corresponding parts of female rats in ovariectomized rats was significantly increased (p<0.01, p<0.001), indicating that both RG3 and Nilestriol significantly increased the bone mineral content of ovariectomized rats.

Test Example 2 Experimental study on the effect of 20(R)-ginsenoside Rg3 on osteoporosis

1 experimental material

1.1 drugs and reagents

20(R)-ginsenoside Rg3 (content>98%), produced by Dalian Fusheng Natural Medicine Development Co., Ltd., batch number: 2012303; ginsenoside Rg3 standard provided by China National Institute for the Control of Pharmaceutical and Biological Products, and HPLC calibration, the content is 98.2%;

Positive control drug: Nilestriol tablets were produced by Beijing Sihuan Pharmaceutical Co., Ltd., National Pharmaceutical Standard Hl1020123, lmg/tablet, 10 tablets/box.

Retinoic acid tablets, produced by Shandong Liangfu Pharmaceutical Co., Ltd., national medicine quasi-word H20083494, 10mg / piece, 20 pieces / box.

Estradiol (E2) Quantitative Assay Kit (Chemiluminescence Method) Xiamen Bosheng Biotechnology Co., Ltd.

Osteocalcin (BGP) test kit Shanghai Guyan Industrial Co., Ltd.

Human calcitonin (CT) enzyme-linked immunosorbent assay kit Shanghai Langton Biotechnology Co., Ltd.

Insulin-like growth factor-receptor I/II (IGF-I/IIR) ELISA kit Shanghai Jianglai Biotechnology Co., Ltd.

1.2 experimental animals

Wistar rats, 50 females, half male and half female, weighing 180g ~ 220, 3 months old, purchased from Experimental Animal Center of Dalian Medical University, quality certificate number: SCXK (13) 2012-0003.

2 experimental methods

2.1 Animal model making

The rats were fed adaptively for 3 days, 10 were randomly selected as the normal control group, and the remaining 40 were modeled. 75 mg/kg.d retinoic acid was administered for 15 days, and the control group was orally administered with the same amount of distilled water.

2.2 Animal grouping

Thirty mice were randomly divided into model group, RG3 group, nylestriol treatment group, plus normal group, a total of 4 groups, 10 in each group.

2.3 treatment methods

After successful modeling and grouping, each group of rats began to be treated with lml/100g dose. The normal group: 0.9% normal saline; the model group: 0.9% normal saline; rg3 group: 6mg/1kg Body weight of rg3; the above four groups of rats were intragastrically administered once a day, the control group: nylestriol was administered, and a suspension of 0.2 mg/ml was prepared with physiological saline before use, and 1 ml/100 g was administered once a week. The stomach is not restricted to eating and drinking, and the cycle is 8 weeks.

2.4 Observation indicators and indicators detection methods

Rat serological examination: After the end of the experiment, the rats in each group were taken with eyeballs, centrifuged, and stored in a refrigerator at -20 °C. The radioimmunoassay method was used to determine the serum of the rats: estradiol (E2), osteocalcin (BGP), calcitonin (CT), and insulin-like growth factor-I (IGI-I), all of which were performed strictly according to the kit instructions.

3 experimental results

Effect of 3.1RG3 on serum E2 in rats

The results of the determination of estradiol (E2) in rat serum are shown in Table 2.

Table 2 Effect of RG3 on serum E2 in rats (x±s)

Group	Number of cases	E2(ng/L)
Normal control group	10	49.13±3.42
Model control group	10	4.28±0.89*
RG3 group	10	31.07±3.16*△□
Positive drug control group	10	23.25±2.84*△

Note: Compared with the normal group *: P <0.01, compared with the model group △: P <0.01, compared with the nylestriol group □: P <0.01.

The experimental results in Table 1 showed that the serum estradiol content was the highest in the normal control group after 8 weeks of administration, and the estradiol content in the RG3 group was significantly increased after administration. Compared with the model group, there was a significant difference ( P <0.01) and significantly better than the control group (P<0.01), indicating that RG3 can significantly increase the estradiol content of experimental animals.

Effect of 3.2RG3 on the effect of serum osteocalcin (BGP) in rats

The results of the determination of osteocalcin (BGP) in rat serum are shown in Table 3.

Table 3 Effect of RG3 on serum osteocalcin (BGP) in rats (x±s)

Note: Compared with the normal group *: P <0.01, compared with the model group △: P <0.01, compared with the nylestriol group □: P <0.01.

It can be seen from Table 3 that after the drug treatment, the serum osteocalcin levels in the rats were compared, and the model control group was significantly different from the normal control group (P<0.01). The RG3 treatment group and the model group and the positive drug (Neil) There was a significant difference in the estradiol group (P<0.01).

Effect of 3.3RG3 on the effect of serum calcitonin (CT) in rats

The results of measuring calcitonin (CT) in rat serum are shown in Table 4.

Table 4 Effect of RG3 on rat CT (x±s)

Note: Compared with the normal group *: P <0.01, compared with the model group △: P <0.01, compared with the nylestriol group □: P <0.01.

From the results of the measurement in Table 4, the serum calcitonin levels in the two treatment groups and the normal control group were higher than those in the model group (P<0.01), and the RG3 group was more effective than the positive drug (nilestriol) group (P<0.01). This experiment shows that RG3 can significantly increase serum calcitonin levels in osteoporotic rats.

Effect of 3.4RG3 on the serum IGI-I (insulin-like growth factor-I) in rats

The results of measuring IGI-I (insulin-like growth factor-I) in rat serum are shown in Table 5.

Table 5 Effect of RG3 on rat IGI-I (x±s)

Note: Compared with the normal group *: P <0.01, and the model group △: P <0.01, □ and nylestriol group: P <0.01.

It can be seen from Table 5 that the serum IGI-I content in the normal control group was the highest after 8 weeks of administration, and the IGI-I content in the RG3 group was significantly increased after administration. Compared with the model group, there was a significant difference (P< 0.01) Comparison between groups, RG3 group was significantly better than the control group after the 8th week (P<0.01), indicating that RG3 can significantly increase the IGI-I content of experimental animals.

Claims (10)

1. 20(R)-Application of ginsenoside Rg3 in the preparation of a medicament or health care product for the treatment of osteoporosis.
2. The use according to claim 1, wherein the drug consists of 20(R)-ginsenoside Rg3 and a pharmaceutically acceptable carrier.
3. The use according to claim 1 or 2, wherein the medicament is in the form of a tablet, a capsule, a pill, a powder, a granule, a syrup, a solution, an emulsion, an injection, a spray, an aerosol, or a gel. Form, cream, expectorant, cataplasm, rubber plaster or plaster.
4. The use according to claim 1 or 2, characterized in that the content of the 20(R)-ginsenoside Rg3 is ≥1%.
5. The use according to Claim 4, characterized in that the content of 20(R)-ginsenoside Rg3 is from 1% to 98%.
6. A medicament or health care product for treating osteoporosis, characterized by comprising 20(R)-ginsenoside Rg3.
7. The pharmaceutical or nutraceutical according to claim 6, wherein the ratio of the weight of the 20(R)-ginsenoside Rg3 to the total weight of the drug or health care product is from 0.01 to 10:100.
8. The pharmaceutical or nutraceutical according to claim 6, wherein the content of 20(R)-ginsenoside Rg3 is ≥1%.
9. The pharmaceutical or nutraceutical according to claim 8, wherein the 20(R)-ginsenoside Rg3 is contained in an amount of from 1% to 98%.
10. The medicine or health care product according to claim 6, which further comprises astragalus extract, salvia miltiorrhiza extract, epimedium extract, hawthorn extract, licorice extract, black sesame extract, ginger extract, grape seed Extract, garnet extract, plant essential oil, arbutin, vitamin C and its derivatives or vitamin E and its derivatives One or more of them.